Trials / Completed
CompletedNCT05403749
A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
A Multi-center, Randomized, Double-masked, Active-controlled Study to Evaluate the Longer Interval of Intravitreal (IVT) Injection of IBI302 in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed for multi-center, randomized, double-masked, active-controlled study to evaluate the longer interval of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | dose 1 IBI302 | After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol. |
| DRUG | Aflibercept | Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month |
| BIOLOGICAL | dose 2 IBI302 | After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol |
Timeline
- Start date
- 2022-06-29
- Primary completion
- 2024-05-13
- Completion
- 2024-05-13
- First posted
- 2022-06-03
- Last updated
- 2024-06-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05403749. Inclusion in this directory is not an endorsement.